CN108018259B - 一种维持人胚胎干细胞自我更新状态的培养方法 - Google Patents

一种维持人胚胎干细胞自我更新状态的培养方法 Download PDF

Info

Publication number
CN108018259B
CN108018259B CN201711223223.4A CN201711223223A CN108018259B CN 108018259 B CN108018259 B CN 108018259B CN 201711223223 A CN201711223223 A CN 201711223223A CN 108018259 B CN108018259 B CN 108018259B
Authority
CN
China
Prior art keywords
ser
ala
gly
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711223223.4A
Other languages
English (en)
Other versions
CN108018259A (zh
Inventor
叶守东
尤宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui University
Original Assignee
Anhui University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui University filed Critical Anhui University
Priority to CN201711223223.4A priority Critical patent/CN108018259B/zh
Publication of CN108018259A publication Critical patent/CN108018259A/zh
Application granted granted Critical
Publication of CN108018259B publication Critical patent/CN108018259B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0606Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/115Basic fibroblast growth factor (bFGF, FGF-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/16Activin; Inhibin; Mullerian inhibiting substance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种维持人胚胎干细胞自我更新状态的培养方法,包括人的胚胎干细胞在本发明培养条件下的传代和培养,以及对本发明条件下培养的人的胚胎干细胞自我更新状态进行观察与检测。本发明方法通过添加Wnt/β‑catenin信号通路的抑制剂解决了目前传统培养条件下人胚胎干细胞状态易分化、传代操作复杂、培养条件成本高和不利于后续机制研究等问题,具有效果稳定、经济高效、操作简单、便于研究等优点,同时也为改善和建立其他种类和物种的多能干细胞的培养条件提供线索,对于未来干细胞基础与应用研究的顺利开展具有积极的推动作用。

Description

一种维持人胚胎干细胞自我更新状态的培养方法
技术领域
本发明涉及人的胚胎干细胞的培养条件,尤其是涉及一种维持人胚胎干细胞自我更新状态的培养方法。
背景技术
干细胞是一种具有自我更新的多潜能细胞,它从早期胚胎中分离,并且能在体外培养条件下能存活且具有无限增殖(自我更新)的能力,同时还保持着分化为机体各种类型细胞的潜能(分化),现已成为研究基因功能、筛选药物和制造疾病动物模型的强有力工具之一,在再生医学领域具有巨大的应用前景。小鼠胚胎干细胞(mouse Embryonic StemCells,mESCs),这是第一株在体外成功建立的干细胞系。其后在1998年,“干细胞之父”Thomson首次建成人类的ESC系。小鼠与人ESCs虽然拥有一些共同的特征,但二者的生物学特性却有诸多不同之处。小鼠的ESC体外培养可以在体外直接使用含胎牛血清(FBS)和白血病抑制因子(LIF)的培养基进行培养,人的ESCs因为不能直接使用小鼠的培养条件,所以一般接种于饲养层细胞上,培养加含血清替代物(KSR)以及细胞因子Activin A和bFGF的培养基中,其中饲养层细胞可以用基质胶Matrigel代替,传代时需要手动切割,以团块的形式进行培养。这种条件培养的人胚胎干细胞的方法不仅耗时、费力,且传代后的细胞存活力低、容易分化很不稳定,经常在传时易凋亡、易分化,易污染,对操作人员的要求较高,不利于目前人胚胎干细胞的基础研究,同时也阻碍了应用研究对于人胚胎干细胞数量的要求,故改善人的胚胎干细胞在体外的培养条件目前成为亟待解决的问题之一,也成为一个研究热点,具有重要的科研价值与学术意义,相关成果有助于未来对于干细胞的安全应用。
虽然传统的Activin A+bFGF培养条件可以维持人的ESCs的生长与自我更新状态,但由于经过多次传代之后,细胞易分化,自我更新能力减弱,不利于后续对于细胞内相关信号通路与分子机制的深入探究以及应用研究。为了优化人的胚胎干细胞的培养条件,安徽大学干细胞与转化医学研究中心的叶守东博士利用CTK消化液实现了人胚胎干细胞的快速消化传代,同时通过一个小分子化合物库,筛选出Wnt/β-catenin信号通路的多种小分子抑制剂(IWR1,XAV939,JW55和53AH)均能够有效地提高人胚胎干细胞的自我更新能力。最终,人胚胎干细胞可被快速进行消化处理,存活能力显著提高,克隆形态均一,生长状况良好,多次传代后仍维持在均一的未分化状态。
因此,本发明在基于Activin A+bFGF培养条件础上,通过添加小分子化合物IWR1,进一步改进与优化了人胚胎干细胞的生长条件,优化后的条件使用三种小分子即可在体外长期稳定地维持人胚胎干细胞的自我更新状态,具有省时、省力、省钱,利于人胚胎干细胞后续的基础和应用研究。
发明内容
为了解决传统培养条件中出现的人胚胎干细胞状态不稳定、传代操作不方便以及现有培养条件成本高和不利于后续探究等问题,本发明提供了一种维持人胚胎干细胞自我更新状态的培养方法。
本发明是通过以下技术方案实现的:
一种维持人胚胎干细胞自我更新状态的培养方法,包括以下步骤:
(1)人的胚胎干细胞HES2或H9(Human Embryonic Stem Cell,hESCs)的获取;实验中所使用的人的胚胎干细胞由美国南加州大学应其龙教授提供;
(2)人的胚胎干细胞在Activin A+bFGF+IWR1条件下的传代和培养:
a、取一个6孔细胞培养板,每孔用1.8-2.1ml DMEM+8-12μl Matrigel包板,置于35-38℃、4.5-5.5%CO2浓度的细胞培养箱内,包被3.8-4.2小时;
b、取生长至70-80%密度的人的胚胎干细胞,弃培养液,用PBS洗涤细胞1次,以除去细胞表面残留的培养液;
c、加入0.9-1.1ml CTK消化胚胎干细胞,6.5-7.5min,细胞边缘浮起,弃CTK,加1.6-2.4ml含9-12%FBS的常规细胞培养液,用移液器吹打,将细胞从培养板上吹打下来,然后转移至15ml无菌离心管中;
d、转速1100-1300rpm,离心3.5-4.5min后,吸去上清;
e、加1.8-2.2ml含9.6-10.2%KSR的N2B27重悬细胞;
其中,5ml N2B27含1.875ml DMEM/F12,0.25ml N2,1.875ml Neurobasal medium,0.5ml B27,2mM L-glutamine,0.1mMβ-mercaptoethanol;
f、在显微镜下利用血球计数板对悬液中的细胞进行计数,并以此计算出细胞的密度;
g、取步骤a已包被好的培养皿,弃包板溶液,向培养板每孔内加入1.8-2.2mlN2B27+KSR培养基;
h、向培养基中加入3.8×104-4.1×104个细胞,水平十字形晃动,使细胞均匀分布;
i、依次添加3.9-4.2μM IWR1、4.9-5.2ng Activin A和4.9-5.2ng bFGF,水平十字形晃动,使其混合均匀,为实验组;
同时设置两组培养条件作为对照:对照组A只加等量Activin A和bFGF;对照组B不加外源性因子;
j、将细胞培养皿置于35-38℃、4-6%CO2浓度的细胞培养箱内培养,即可。
其中,所述CTK消化胚胎干细胞含0.09-0.12%Collagenase IV+0.24-0.26%Trypsin+19-21%KSR+0.9-1.1mM CaCl2的PBS。
其中,人胚胎干细胞自我更新与细胞特性检测方法如下:
(1)形态观察:使用Leica DMIL倒置相差显微镜对Activin A+bFGF+IWR1条件下、不同培养天数的人的胚胎干细胞进行观察,以细胞形态特征进行检测,发现细胞逐渐形成扁平的单层或多层形态,细胞之间堆积紧密,集落边界清晰,符合自我更新的形态特征;
将细胞多次传代后,观察不同代数细胞的培养形态:实验组人胚胎干细胞保持自我更新的特征;对照组A细胞出现部分分化;对照组B细胞全部分化。
(2)AP染色检测细胞自我更新情况,具体方法如下:
在实验组、对照组A与对照组B细胞传代培养5代后进行AP染色;
a、首先配置染色剂,将一个8523R胶囊(SIGMA-ALDRICH)溶入48ml的水中放在3-5℃避光保存,取适量,将其与SLBJ6060V(SIGMA-ALDRICH)按25:1的比例充分混合成染色剂;
b、将不同培养条件下培养好的干细胞,弃培养液,加PBS洗一遍,加0.9-1.2ml的3.8-4.2%多聚甲醛固定细胞1.5-2.5分钟;
c、弃多聚甲醛,加PBS洗两遍,把多聚甲醛残留洗掉,每个培养孔2ml的染色剂,避光静置38-43分钟;
d、弃染色液,用PBS洗两遍,加适量PBS后放在Leica DMIL倒置相差显微镜观察拍照,观察的着色状态,判断细胞的自我更新状态;
观察的着色状态,可以观察到对照组B细胞无色,说明已经分化,实验组细胞和对照组A细胞被染成红色,符合自我更新的特征。
(3)免疫荧光染色检测自我更新标志蛋白TRA-1-81和Oct4的表达,具体方法如下:
a、将实验组与对照组A、B细胞传代培养5代后,弃培养液,用PBS漂洗细胞1次,加入3.8-4.2%浓度的多聚甲醛,室温固定18-22min;
b、弃多聚甲醛,用PBS漂洗细胞1次,分别加入含4.5-5.5%浓度牛血清白蛋白、0.15-0.22%浓度Triton X-100的PBS封闭液、含4.5-5.5%浓度牛血清白蛋白的PBS封闭液,用于分别检测Oct4、TRA-81基因表达情况,将细胞置于36-38℃温箱,孵育0.9-1.2h;
c、弃封闭液,用PBS漂洗细胞1次,而后分别加入含有TRA-81(1:200,Santa Cruz)一抗的稀释液、含有Oct4(1:200,Santa Cruz)一抗的稀释液,3-5℃过夜;
d、次日,弃一抗,用PBS漂洗细胞3次,每4.5-5.5min洗一次,而后分别加入携带有488荧光基团的二抗(1:1000,碧云天)以及Hoechs(1:5000,Invitrogen)染料的稀释液,用锡箔纸包住培养板,36-38℃避光孵育0.9-1.2h;
e、弃二抗稀释液,用PBS漂洗细胞3次,每2.5-3.5min洗一次,而后在LeicaDMI3000B型倒置荧光显微镜下观察并拍照,检测细胞的自我更新状态;
其中,Oct4蛋白一抗为鼠来源,TRA-81蛋白一抗为鼠来源,二抗均为带488荧光基团的羊抗鼠抗体,在荧光显微镜下观察时呈现绿色荧光;同时Hoechst染料可以对细胞核进行染色,荧光显微镜下呈现蓝色荧光;
免疫荧光结果显示,添加细胞外源性因子的实验组细胞、对照组A细胞均高表达TRA-1-81和Oct4,说明细胞处于自我更新的状态,而对照组B细胞已经分化;
其中,所述(3)步骤c中,稀释液是指含4.8-5.3%浓度牛血清白蛋白、0.18-0.22%浓度Triton X-100、0.9-1.1%浓度N3Na的PBS。
其中,所述(3)步骤d中,稀释液是指含4.5-5.5%浓度牛血清白蛋白的PBS。
(4)实时荧光定量PCR(qRT-PCR)检测自我更新标志基因Nanog、Oct4和Prdm14以及细胞分化标志基因Mixl1、Gata6和Gata4的表达水平,具体方法如下:
取生长至70-80%密度的实验组与对照组A、B细胞,采用Trizol法抽提细胞总RNA,具体方法如下:
弃培养液,用PBS洗涤细胞2次,加入500μl Trizol裂解细胞,用移液器反复吹打2min后,转移至1.5ml离心管中;
向离心管中加入100μl三氯甲烷,用力摇晃15s,静置2min后4℃离心10min,12000rpm;
将上清吸取到另一个干净的离心管中,注意不要吸到中间层;按1:1的比例向上清中加入异丙醇,轻摇使之混匀,静置10min后4℃离心10min;
离心后可在管底看到少量白色沉淀,弃上清,向离心管中加入1ml 75%浓度的乙醇,上下倒转、摇晃、轻弹;
4℃离心5min,弃上清,加入1ml 75%浓度的乙醇,4℃离心5min后,弃上清,将离心管倒立于干净的吸水纸上,待管底的白色沉淀变透明后,加入40-50μl ddH2O,置于4℃或-20℃保存;
获得待测细胞的总RNA后,利用TransScript All-in-One First-Strand cDNASynthesis SuperMix for qPCR(TransGen Biotech,China)试剂盒,完成人胚胎干细胞cDNA的合成;
以合成好的cDNA为模板,参照TransStart Tip Green qPCR SuperMix(TransGenBiotech,China)试剂盒,在Thermo PikoReal 96实时荧光定量PCR仪上进行基因表达水平的检测:
以GAPDH为内参基因,各引物序列如下:
qRT-PCR结果显示,与对照组A、B相比,实验组条件Activin A+bFGF+IWR1培养的人胚胎干细胞相较于对照组A、B条件(即Activin A+bFGF和不添加细胞因子组)培养的细胞相比,实验组培养的细胞表达的Nanog、Oct4以及Prdm14明显高于对照组,而Mixl1、Gata6和Gata4三种基因表达量明显低于对照组,说明在转录水平上,实验组细胞处于更稳定的自我更新状态。
本发明具有如下优点:
(1)本发明采用Matrigel包板,在培养基N2B27+KSR中加入Activin A+bFGF+IWR1三种小分子化合物来培养人胚胎干细胞,在此种培养条件下,细胞生长情况良好,能够维持自我更新的状态,经过多次传代,均未出现分化现象。
(2)与现有的Activin A+bFGF培养条件相比,本发明能更长久保持干细胞的自我更新能力,使干细胞能在体外长时间培养,有利于人胚胎干细胞未来的基础和应用研究。
(3)本发明多摸索出来的培养条件,比传统培养条件(饲养层细胞培养),更经济省时,易于操作。
(4)本发明所摸索出的培养条件,为改善目前人的胚胎干细胞以及其他种类和物种的多能性干细胞的培养条件提供线索。
附图说明
构成本申请的一部分的说明书附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。在附图中,ActivinA+bFGF+IWR1条件下培养的细胞,记为ABI;Activin A+bFGF条件下培养的细胞,记为AB;不添加外源性因子的细胞,记为None;
图1为三种条件下培养5代以后的HES2人胚胎干细胞在相差显微镜下的形态图;其中ABI细胞处于自我更新状态,AB细胞符合自我更新状态的特征,None细胞处于分化状态;
图2为三种条件下培养5代后的人胚胎干细胞AP染色图;其中未被分化的细胞染成红色,而分化的细胞不着色;
图3为三种条件下培养5代后的人胚胎干细胞免疫荧光染色图;在荧光显微镜下观察时,Oct4与TRA-1-81蛋白呈现绿色荧光,Hoechst染料用来显示细胞核的位置,呈现蓝色荧光;
图4为三种条件下培养5代后人胚胎干细胞中自我更新标志基因以及特性基因相对表达量的直方图;
图5为实施例1培养的HES2人胚胎干细胞在相差显微镜下的形态图;
图6为实施例1实验组与对照组B培养人胚胎干细胞免疫荧光染色图;
图7为实施例1实验组与对照组B培养人胚胎干细胞中自我更新标志基因以及特性基因相对表达量的直方图。
具体实施方式
实施例1
(1)HES2人胚胎干细胞(Human Embryonic Stem Cell,hESCs)由美国南加州大学应其龙教授提供;
(2)HES2人胚胎干细胞在Activin A+BFGF+IWR1条件下的传代和培养:
a、取一个6孔细胞培养板,每孔用2ml DMEM+10μl Matrigel包板,置于37℃、5%CO2浓度的细胞培养箱内,包被4小时;
b、取生长至70-80%密度的人的胚胎干细胞,弃培养液,用PBS洗涤细胞1次,以除去细胞表面残留的培养液;
c、加入1ml CTK,消化胚胎干细胞,7min左右,细胞边缘浮起,弃CTK,加2ml含10%FBS的常规细胞培养液,用移液器吹打,将细胞从培养板上吹打下来,然后转移至15ml无菌离心管中;
d、1200rpm,离心4min后,吸去上清;
e、加2ml含10%KSR的N2B27培养液重悬细胞;
其中,5ml N2B27含1.875ml DMEM/F12,0.25ml N2,1.875ml Neurobasal medium,0.5ml B27,2mM L-glutamine,0.1mMβ-mercaptoethanol;
f、在显微镜下利用血球计数板对悬液中的细胞进行计数,并以此计算出细胞的密度;
j、取步骤a已包被好的培养皿,弃包板溶液,向培养板每孔内加入2ml N2B27/KSR培养基;
h、向培养基中加入5×104个细胞,水平十字形晃动,使细胞均匀分布,为实验组;
同时设置对照组B不加外源性因子;
i、依次添加4μM IWR1、5ng Activin A和5ng bFGF,水平十字形晃动,使其混合均匀。
j、将细胞培养皿置于37℃、5%CO2浓度的细胞培养箱内培养。
(3)自我更新与细胞特性检测
1)形态观察:使用Leica DMIL倒置相差显微镜对Activin A+bFGF+IWR1条件下、传代5代后的人胚胎干细胞进行观察,发现细胞逐渐形成扁平的单层形态,细胞之间堆积紧密,集落边界清晰,符合自我更新的形态特征,如附图5所示。
2)免疫荧光染色检测:
将实验组与对照组B细胞传代培养5代后,弃培养液,用PBS漂洗细胞1次,加入4%浓度的多聚甲醛,室温固定20min;
b、弃多聚甲醛,用PBS漂洗细胞1次,加入含5%浓度牛血清白蛋白、0.2%浓度Triton X-100的PBS封闭液,将细胞置于37℃温箱,孵育1h;
c、弃封闭液,用PBS漂洗细胞1次,而后分别加入含有TRA-81(1:200,Santa Cruz)一抗的稀释液、含有Oct4(1:200,Santa Cruz)一抗的稀释液,4℃过夜;
d、次日,弃一抗,用PBS漂洗细胞3次,每5min洗一次,而后分别加入携带有488荧光基团的二抗(1:1000,碧云天)以及Hoechst(1:5000,Invitrogen)染料的稀释液,用锡箔纸包住培养板,37℃避光孵育1h;
e、弃二抗稀释液,用PBS漂洗细胞3次,在Leica DMI3000B型倒置荧光显微镜下观察并拍照,结果如附图6所示。
3)实时荧光定量PCR(qRT-PCR):
利用Primer3Plus网站设计Nanog、Oct4、Prdm14、Mixl1、Gata6、Gata4及GAPDH七种基因的引物序列,其中,Nanog、Oct4和Prdm14为自我更新标志基因,Mixl1、Gata6和Gata4为细胞分化标志基因,GAPDH作为内参基因;引物设计完成后交由上海生工公司进行合成;
待实验组与对照组B细胞生长到80%覆盖密度后,采用Trizol法分别抽提每组细胞的总RNA;
以每组细胞的总RNA为模板,利用TransScript All-in-One First-Strand cDNASynthesis SuperMix for qPCR(TransGen Biotech)试剂盒,将总RNA逆转录成cDNA;分别将cDNA与各引物稀释到所需浓度,依照TransStart Tip Green qPCR SuperMix(TransGenBiotech)试剂盒说明书提供的反应体系与扩增程序,在Thermo PikoReal 96实时荧光定量PCR仪上进行相关操作;
反应完成后,利用与荧光定量PCR仪配套的Piko Real Software 2.2软件,查看并导出熔解曲线、Ct值等关键参数;
以对照组细胞中相应基因的表达量为参照值“1”,根据Ct值等参数信息、利用GraphPad Prism 5绘图软件绘制各基因相对表达量的直方图,如附图7所示。qRT-PCR结果显示,与对照组B相比,实验组中Nanog、Oct4以及Prdm14三种自我更新标志基因表达水平更高,实验组Mixl1、Gata6和Gata4三种分化标志基因表达水平更低,说明在转录水平上,Activin A+bFGF+IWR1条件下培养5代后人的胚胎干细胞处于更稳定的未分化状态。
序列表
<110> 安徽大学
<120> 一种维持人胚胎干细胞自我更新状态的培养方法
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 882
<212> DNA
<213> GAPDH
<400> 1
atggtttaca tgttccaata tgattccacc catggcaaat tccatggcac cgtcaaggct 60
gagaacggga agcttgtcat caatggaaat cccatcacca tcttccagga gcgagatccc 120
tccaaaatca agtggggcga tgctggcgct gagtacgtcg tggagtccac tggcgtcttc 180
accaccatgg agaaggctgg ggctcatttg caggggggag ccaaaagggt catcatctct 240
gccccctctg ctgatgcccc catgttcgtc atgggtgtga accatgagaa gtatgacaac 300
agcctcaaga tcatcagcaa tgcctcctgc accaccaact gcttagcacc cctggccaag 360
gtcatccatg acaactttgg tatcgtggaa ggactcatga ccacagtcca tgccatcact 420
gccacccaga agactgtgga tggcccctcc gggaaactgt ggcgtgatgg ccgcggggct 480
ctccagaaca tcatccctgc ctctactggc gctgccaagg ctgtgggcaa ggtcatccct 540
gagctgaacg ggaagctcac tggcatggcc ttccgtgtcc ccactgccaa cgtgtcagtg 600
gtggacctga cctgccgtct agaaaaacct gccaaatatg atgacatcaa gaaggtggtg 660
aagcaggcgt cggagggccc cctcaagggc atcctgggct acactgagca ccaggtggtc 720
tcctctgact tcaacagcga cacccactcc tccacctttg acgctggggc tggcattgcc 780
ctcaacgacc actttgtcaa gctcatttcc tggtatgaca acgaatttgg ctacagcaac 840
agggtggtgg acctcatggc ccacatggcc tccaaggagt aa 882
<210> 2
<211> 292
<212> PRT
<213> GAPDH
<400> 2
Met Val Tyr Met Phe Gln Tyr Asp Ser Thr His Gly Lys Phe His Gly
1 5 10 15
Thr Val Lys Ala Glu Asn Gly Lys Leu Val Ile Asn Gly Asn Pro Ile
20 25 30
Thr Ile Phe Gln Glu Arg Asp Pro Ser Lys Ile Lys Trp Gly Asp Ala
35 40 45
Gly Ala Glu Tyr Val Val Glu Ser Thr Gly Val Phe Thr Thr Met Glu
50 55 60
Lys Ala Gly Ala His Leu Gln Gly Gly Ala Lys Arg Ile Ile Ser Ala
65 70 75 80
Pro Ser Ala Asp Ala Pro Met Phe Val Met Gly Val Asn His Glu Lys
85 90 95
Tyr Asp Asn Ser Leu Lys Ile Ile Ser Asn Ala Ser Cys Thr Thr Asn
100 105 110
Cys Leu Ala Pro Leu Ala Lys Val Ile His Asp Asn Phe Gly Ile Val
115 120 125
Glu Gly Leu Met Thr Thr Val His Ala Ile Thr Ala Thr Gln Lys Thr
130 135 140
Val Asp Gly Pro Ser Gly Lys Leu Trp Arg Asp Gly Arg Gly Ala Leu
145 150 155 160
Gln Asn Ile Ile Pro Ala Ser Thr Gly Ala Ala Lys Ala Val Gly Lys
165 170 175
Val Ile Pro Glu Leu Asn Gly Lys Leu Thr Gly Met Ala Phe Arg Val
180 185 190
Pro Thr Ala Asn Val Ser Val Val Asp Leu Thr Cys Arg Leu Glu Lys
195 200 205
Pro Ala Lys Tyr Asp Asp Ile Lys Lys Val Val Lys Gln Ala Ser Glu
210 215 220
Gly Pro Leu Lys Gly Ile Leu Gly Tyr Thr Glu His Gln Val Val Ser
225 230 235 240
Ser Asp Phe Asn Ser Asp Thr His Ser Ser Thr Phe Asp Ala Gly Ala
245 250 255
Gly Ile Ala Leu Asn Asp His Phe Val Lys Leu Ile Ser Trp Tyr Asp
260 265 270
Asn Glu Phe Gly Tyr Ser Asn Arg Val Val Asp Leu Met Ala His Met
275 280 285
Ala Ser Lys Glu
290
<210> 1
<211> 870
<212> DNA
<213> Nanog
<400> 1
atgagtgtgg atccagcttg tccccaaagc ttgccttgct ttgaagcatc cgactgtaaa 60
gaatcttcac ctatgcctgt gatttgtggg cctgaagaaa actatccatc cttgcaaatg 120
tcttctgctg agatgcctca cacggagact gtctctcctc ttccttcctc catggatctg 180
cttattcagg acagccctga ttcttccacc agtcccaaag gcaaacaacc cacttctgca 240
gagaagagtg tcgcaaaaaa ggaagacaag gtcccggtca agaaacagaa gaccagaact 300
gtgttctctt ccacccagct gtgtgtactc aatgatagat ttcagagaca gaaatacctc 360
agcctccagc agatgcaaga actctccaac atcctgaacc tcagctacaa acaggtgaag 420
acctggttcc agaaccagag aatgaaatct aagaggtggc agaaaaacaa ctggccgaag 480
aatagcaatg gtgtgacgca gggatgcctg gtgaacccga ctgggaacct tccaatgtgg 540
agcaaccaga cctggaacaa ttcaacctgg agcaaccaga cccagaacat ccagtcctgg 600
agcaaccact cctggaacac tcagacctgg tgcacccaat cctggaacaa tcaggcctgg 660
aacagtccct tctataactg tggagaggaa tctctgcagt cctgcatgca gttccagcca 720
aattctcctg ccagtgactt ggaggctgcc ttggaagctg ctggggaagg ccttaatgta 780
atacagcaga ccactaggta ttttagtact ccacaaacca tggatttatt cctaaactac 840
tccatgaaca tgcaacctga agacgtgtga 870
<210> 2
<211> 289
<212> PRT
<213> Nanog
<400> 2
Met Ser Val Asp Pro Ala Cys Pro Gln Ser Leu Pro Cys Phe Glu Ala
1 5 10 15
Ser Asp Cys Lys Glu Ser Ser Pro Met Pro Val Ile Cys Gly Pro Glu
20 25 30
Glu Asn Tyr Pro Ser Leu Gln Met Ser Ser Ala Glu Met Pro His Thr
35 40 45
Glu Thr Val Ser Pro Leu Pro Ser Ser Met Asp Leu Leu Ile Gln Asp
50 55 60
Ser Pro Asp Ser Ser Thr Ser Pro Lys Gly Lys Gln Pro Thr Ser Ala
65 70 75 80
Glu Lys Ser Val Ala Lys Lys Glu Asp Lys Val Pro Val Lys Lys Gln
85 90 95
Lys Thr Arg Thr Val Phe Ser Ser Thr Gln Leu Cys Val Leu Asn Asp
100 105 110
Arg Phe Gln Arg Gln Lys Tyr Leu Ser Leu Gln Gln Met Gln Glu Leu
115 120 125
Ser Asn Ile Leu Asn Leu Ser Tyr Lys Gln Val Lys Thr Trp Phe Gln
130 135 140
Asn Gln Arg Met Lys Ser Lys Arg Trp Gln Lys Asn Asn Trp Pro Lys
145 150 155 160
Asn Ser Asn Gly Val Thr Gln Gly Cys Leu Val Asn Pro Thr Gly Asn
165 170 175
Leu Pro Met Trp Ser Asn Gln Thr Trp Asn Asn Ser Thr Trp Ser Asn
180 185 190
Gln Thr Gln Asn Ile Gln Ser Trp Ser Asn His Ser Trp Asn Thr Gln
195 200 205
Thr Trp Cys Thr Gln Ser Trp Asn Asn Gln Ala Trp Asn Ser Pro Phe
210 215 220
Tyr Asn Cys Gly Glu Glu Ser Leu Gln Ser Cys Met Gln Phe Gln Pro
225 230 235 240
Asn Ser Pro Ala Ser Asp Leu Glu Ala Ala Leu Glu Ala Ala Gly Glu
245 250 255
Gly Leu Asn Val Ile Gln Gln Thr Thr Arg Tyr Phe Ser Thr Pro Gln
260 265 270
Thr Met Asp Leu Phe Leu Asn Tyr Ser Met Asn Met Gln Pro Glu Asp
275 280 285
Val
<210> 1
<211> 573
<212> DNA
<213> Oct4
<400> 1
ctgggggttc tatttgggaa ggtattcagc caaacgacca tctgccgctt tgaggctctg 60
cagcttagct tcaagaacat gtgtaagctg cggcccttgc tgcagaagtg ggtggaggaa 120
gctgacaaca atgaaaatct tcaggagata tgcaaagcag aaaccctcgt gcaggcccga 180
aagagaaagc gaaccagtat cgagaaccga gtgagaggca acctggagaa tttgttcctg 240
cagtgcccga aacccacact gcagcagatc agccacatcg cccagcagct tgggctcgag 300
aaggatgtgg tccgagtgtg gttctgtaac cggcgccaga agggcaagcg atcaagcagc 360
gactatgcac aacgagagga ttttgaggct gctgggtctc ctttctcagg gggaccagtg 420
tcctttcctc tggccccagg gccccatttt ggtaccccag gctatgggag ccctcacttc 480
actgcactgt actcctcggt ccctttccct gagggggaag cctttccccc tgtctccgtc 540
accactctgg gctctcccat gcattcaaac tga 573
<210> 2
<211> 190
<212> PRT
<213> Oct4
<400> 2
Met Gly Val Leu Phe Gly Lys Val Phe Ser Gln Thr Thr Ile Cys Arg
1 5 10 15
Phe Glu Ala Leu Gln Leu Ser Phe Lys Asn Met Cys Lys Leu Arg Pro
20 25 30
Leu Leu Gln Lys Trp Val Glu Glu Ala Asp Asn Asn Glu Asn Leu Gln
35 40 45
Glu Ile Cys Lys Ala Glu Thr Leu Val Gln Ala Arg Lys Arg Lys Arg
50 55 60
Thr Ser Ile Glu Asn Arg Val Arg Gly Asn Leu Glu Asn Leu Phe Leu
65 70 75 80
Gln Cys Pro Lys Pro Thr Leu Gln Gln Ile Ser His Ile Ala Gln Gln
85 90 95
Leu Gly Leu Glu Lys Asp Val Val Arg Val Trp Phe Cys Asn Arg Arg
100 105 110
Gln Lys Gly Lys Arg Ser Ser Ser Asp Tyr Ala Gln Arg Glu Asp Phe
115 120 125
Glu Ala Ala Gly Ser Pro Phe Ser Gly Gly Pro Val Ser Phe Pro Leu
130 135 140
Ala Pro Gly Pro His Phe Gly Thr Pro Gly Tyr Gly Ser Pro His Phe
145 150 155 160
Thr Ala Leu Tyr Ser Ser Val Pro Phe Pro Glu Gly Glu Ala Phe Pro
165 170 175
Pro Val Ser Val Thr Thr Leu Gly Ser Pro Met His Ser Asn
180 185 190
<210> 1
<211> 1716
<212> DNA
<213> Prdm14
<400> 1
atggctctac cccggccaag tgaggccgtg cctcaggaca aggtgtgcta cccgccggag 60
agcagcccgc agaacctggc cgcgtactac acgcctttcc cgtcctatgg acactacaga 120
aacagcctgg ccaccgtgga ggaagacttc caacctttcc ggcagctgga ggccgcagcg 180
tctgctgccc ccgccatgcc ccccttcccc ttccggatgg cgcctccctt gctgagcccg 240
ggtctgggcc tacagaggga gcctctctac gatctgccct ggtacagcaa gctgccaccg 300
tggtacccaa ttccccacgt ccccagggaa gtgccgccct tcctgagcag cagccacgag 360
tacgcgggtg ccagcagtga agatctgggc caccaaatca ttggtggcga caacgagagt 420
ggcccgtgtt gtggacctga cactttaatt ccaccgcccc ctgcggatgc ttctctgtta 480
cctgaggggc tgaggacctc ccagttatta ccttgctcac ccagcaagca gtcagaggat 540
ggtcccaaac cctccaacca agaagggaag tcccctgctc ggttccagtt cacggaggag 600
gacctgcact tcgttctgta cggggtcact cccagcctgg agcacccagc cagcctgcac 660
catgcgattt caggcctcct ggtcccccca gacagctctg gatctgattc tcttcctcaa 720
actctggata aagactccct tcaacttcca gaaggtctat gcctcatgca gacggtgttt 780
ggtgaagtcc cacattttgg tgtgttctgc agtagtttta tcgccaaagg agtcaggttt 840
gggccctttc aaggtaaagt ggtcaatgcc agtgaagtga agacctacgg agacaattct 900
gtgatgtggg agatctttga agatggtcat ttgagccact ttatagatgg aaaaggaggt 960
acggggaact ggatgtccta tgtcaactgt gcccgcttcc ccaaggagca gaacctagtt 1020
gctgtgcagt gtcaagggca tatattttat gagagctgca aagagatcca tcagaaccaa 1080
gagctccttg tgtggtatgg agactgctat gagaaatttc tggatattcc tgtgagcctt 1140
caggtcacag agccggggaa gcagccatct gggccctctg aagagtctgc agaaggctac 1200
agatgtgaaa gatgtgggaa ggtatttacc tacaaatatt acagagataa gcacctcaag 1260
tacaccccct gtgtggacaa gggcgatagg aaatttccct gttctctctg caaacgatcc 1320
tttgagaagc gggaccggct tcggatccac attcttcatg ttcatgagaa gcaccggcct 1380
cacaagtgtt ctacatgtgg gaaatgtttc tctcaatctt ccagcctaaa caaacacatg 1440
cgagtccact ctggagacag accataccag tgtgtgtatt gtactaagag gttcacagcc 1500
tccagcatac tccgcacaca catcaggcag cactccgggg agaagccctt caaatgcaag 1560
tactgtggta aatcttttgc atcccatgct gcccatgaca gccatgtccg gcgttcacac 1620
aaggaggatg atggctgctc atgcagcatc tgtgggaaaa tcttctcaga tcaagaaaca 1680
ttctactccc acatgaagtt tcatgaagac tactag 1716
<210> 2
<211> 571
<212> PRT
<213> Prdm14
<400> 2
Met Ala Leu Pro Arg Pro Ser Glu Ala Val Pro Gln Asp Lys Val Cys
1 5 10 15
Tyr Pro Pro Glu Ser Ser Pro Gln Asn Leu Ala Ala Tyr Tyr Thr Pro
20 25 30
Phe Pro Ser Tyr Gly His Tyr Arg Asn Ser Leu Ala Thr Val Glu Glu
35 40 45
Asp Phe Gln Pro Phe Arg Gln Leu Glu Ala Ala Ala Ser Ala Ala Pro
50 55 60
Ala Met Pro Pro Phe Pro Phe Arg Met Ala Pro Pro Leu Leu Ser Pro
65 70 75 80
Gly Leu Gly Leu Gln Arg Glu Pro Leu Tyr Asp Leu Pro Trp Tyr Ser
85 90 95
Lys Leu Pro Pro Trp Tyr Pro Ile Pro His Val Pro Arg Glu Val Pro
100 105 110
Pro Phe Leu Ser Ser Ser His Glu Tyr Ala Gly Ala Ser Ser Glu Asp
115 120 125
Leu Gly His Gln Ile Ile Gly Gly Asp Asn Glu Ser Gly Pro Cys Cys
130 135 140
Gly Pro Asp Thr Leu Ile Pro Pro Pro Pro Ala Asp Ala Ser Leu Leu
145 150 155 160
Pro Glu Gly Leu Arg Thr Ser Gln Leu Leu Pro Cys Ser Pro Ser Lys
165 170 175
Gln Ser Glu Asp Gly Pro Lys Pro Ser Asn Gln Glu Gly Lys Ser Pro
180 185 190
Ala Arg Phe Gln Phe Thr Glu Glu Asp Leu His Phe Val Leu Tyr Gly
195 200 205
Val Thr Pro Ser Leu Glu His Pro Ala Ser Leu His His Ala Ile Ser
210 215 220
Gly Leu Leu Val Pro Pro Asp Ser Ser Gly Ser Asp Ser Leu Pro Gln
225 230 235 240
Thr Leu Asp Lys Asp Ser Leu Gln Leu Pro Glu Gly Leu Cys Leu Met
245 250 255
Gln Thr Val Phe Gly Glu Val Pro His Phe Gly Val Phe Cys Ser Ser
260 265 270
Phe Ile Ala Lys Gly Val Arg Phe Gly Pro Phe Gln Gly Lys Val Val
275 280 285
Asn Ala Ser Glu Val Lys Thr Tyr Gly Asp Asn Ser Val Met Trp Glu
290 295 300
Ile Phe Glu Asp Gly His Leu Ser His Phe Ile Asp Gly Lys Gly Gly
305 310 315 320
Thr Gly Asn Trp Met Ser Tyr Val Asn Cys Ala Arg Phe Pro Lys Glu
325 330 335
Gln Asn Leu Val Ala Val Gln Cys Gln Gly His Ile Phe Tyr Glu Ser
340 345 350
Cys Lys Glu Ile His Gln Asn Gln Glu Leu Leu Val Trp Tyr Gly Asp
355 360 365
Cys Tyr Glu Lys Phe Leu Asp Ile Pro Val Ser Leu Gln Val Thr Glu
370 375 380
Pro Gly Lys Gln Pro Ser Gly Pro Ser Glu Glu Ser Ala Glu Gly Tyr
385 390 395 400
Arg Cys Glu Arg Cys Gly Lys Val Phe Thr Tyr Lys Tyr Tyr Arg Asp
405 410 415
Lys His Leu Lys Tyr Thr Pro Cys Val Asp Lys Gly Asp Arg Lys Phe
420 425 430
Pro Cys Ser Leu Cys Lys Arg Ser Phe Glu Lys Arg Asp Arg Leu Arg
435 440 445
Ile His Ile Leu His Val His Glu Lys His Arg Pro His Lys Cys Ser
450 455 460
Thr Cys Gly Lys Cys Phe Ser Gln Ser Ser Ser Leu Asn Lys His Met
465 470 475 480
Arg Val His Ser Gly Asp Arg Pro Tyr Gln Cys Val Tyr Cys Thr Lys
485 490 495
Arg Phe Thr Ala Ser Ser Ile Leu Arg Thr His Ile Arg Gln His Ser
500 505 510
Gly Glu Lys Pro Phe Lys Cys Lys Tyr Cys Gly Lys Ser Phe Ala Ser
515 520 525
His Ala Ala His Asp Ser His Val Arg Arg Ser His Lys Glu Asp Asp
530 535 540
Gly Cys Ser Cys Ser Ile Cys Gly Lys Ile Phe Ser Asp Gln Glu Thr
545 550 555 560
Phe Tyr Ser His Met Lys Phe His Glu Asp Tyr
565 570
<210> 1
<211> 723
<212> DNA
<213> Mixl1
<400> 1
atggccacag ccgagtcccg tgcgctccag tttgccgagg gcgccgcgtt tccagcgtac 60
cgggcccccc acgccggcgg ggcgctcctg ccgcccccga gccctgcggc agccctgctc 120
cctgcgccgc ccgcgggccc cggcccagcg acctttgcgg gcttcctcgg ccgggacccc 180
gggccggccc cgccgccccc cgccagcctg ggctcgcctg cgccccccaa aggcgcggcc 240
gccccgtcgg cgtcgcagcg ccgcaagcgc acgtctttca gcgccgaaca gctgcagctg 300
ctggagctcg tcttccgccg gacccggtac cccgacatcc acttgcgcga gcgcctggcc 360
gcgctcaccc tgctccccga gtccaggatc cagcttttat tttctcccct cttccaggta 420
tggttccaga acaggcgtgc caagtctcgg cgtcagagtg ggaaatcctt ccaacctttg 480
gctaggccgg agattatcct caaccactgt gctcctggaa ctgaaacgaa atgtctgaag 540
ccccagctgc ctcttgaggt agatgtgaac tgcctgcccg aaccaaacgg ggttggaggg 600
ggcatctctg actctagctc ccaaggtcag aattttgaaa cctgttcccc tctctctgaa 660
gacattggtt caaagctgga ctcatgggag gaacacatct tttctgcctt tggtaacttt 720
tga 723
<210> 2
<211> 240
<212> PRT
<213> Mixl1
<400> 2
Met Ala Thr Ala Glu Ser Arg Ala Leu Gln Phe Ala Glu Gly Ala Ala
1 5 10 15
Phe Pro Ala Tyr Arg Ala Pro His Ala Gly Gly Ala Leu Leu Pro Pro
20 25 30
Pro Ser Pro Ala Ala Ala Leu Leu Pro Ala Pro Pro Ala Gly Pro Gly
35 40 45
Pro Ala Thr Phe Ala Gly Phe Leu Gly Arg Asp Pro Gly Pro Ala Pro
50 55 60
Pro Pro Pro Ala Ser Leu Gly Ser Pro Ala Pro Pro Lys Gly Ala Ala
65 70 75 80
Ala Pro Ser Ala Ser Gln Arg Arg Lys Arg Thr Ser Phe Ser Ala Glu
85 90 95
Gln Leu Gln Leu Leu Glu Leu Val Phe Arg Arg Thr Arg Tyr Pro Asp
100 105 110
Ile His Leu Arg Glu Arg Leu Ala Ala Leu Thr Leu Leu Pro Glu Ser
115 120 125
Arg Ile Gln Leu Leu Phe Ser Pro Leu Phe Gln Val Trp Phe Gln Asn
130 135 140
Arg Arg Ala Lys Ser Arg Arg Gln Ser Gly Lys Ser Phe Gln Pro Leu
145 150 155 160
Ala Arg Pro Glu Ile Ile Leu Asn His Cys Ala Pro Gly Thr Glu Thr
165 170 175
Lys Cys Leu Lys Pro Gln Leu Pro Leu Glu Val Asp Val Asn Cys Leu
180 185 190
Pro Glu Pro Asn Gly Val Gly Gly Gly Ile Ser Asp Ser Ser Ser Gln
195 200 205
Gly Gln Asn Phe Glu Thr Cys Ser Pro Leu Ser Glu Asp Ile Gly Ser
210 215 220
Lys Leu Asp Ser Trp Glu Glu His Ile Phe Ser Ala Phe Gly Asn Phe
225 230 235 240
<210> 1
<211> 1788
<212> DNA
<213> Gata6
<400> 1
atggccttga ctgacggcgg ctggtgcttg ccgaagcgct tcggggccgc gggtgcggac 60
gccagcgact ccagagcctt tccagcgcgg gagccctcca cgccgccttc ccccatctct 120
tcctcgtcct cctcctgctc ccggggcgga gagcggggcc ccggcggcgc cagcaactgc 180
gggacgcctc agctcgacac ggaggcggcg gccggacccc cggcccgctc gctgctgctc 240
agttcctacg cttcgcatcc cttcggggct ccccacggac cttcggcgcc tggggtcgcg 300
ggccccgggg gcaacctgtc gagctgggag gacttgctgc tgttcactga cctcgaccaa 360
gccgcgaccg ccagcaagct gctgtggtcc agccgcggcg ccaagctgag ccccttcgca 420
cccgagcagc cggaggagat gtaccagacc ctcgccgctc tctccagcca gggtccggcc 480
gcctacgacg gcgcgcccgg cggcttcgtg cactctgcgg ccgcggcggc agcagccgcg 540
gcggcggcca gctccccggt ctacgtgccc accacccgcg tgggttccat gctgcccggc 600
ctaccgtacc acctgcaggg gtcgggcagt gggccagcca accacgcggg cggcgcgggc 660
gcgcaccccg gctggcctca ggcctcggcc gacagccctc catacggcag cggaggcggc 720
gcggctggcg gcggggccgc ggggcctggc ggcgctggct cagccgcggc gcacgtctcg 780
gcgcgcttcc cctactctcc cagcccgccc atggccaacg gcgccgcgcg ggagccggga 840
ggctacgcgg cggcgggcag tgggggcgcg ggaggcgtga gcggcggcgg cagtagcctg 900
gcggccatgg gcggccgcga gccccagtac agctcgctgt cggccgcgcg gccgctgaac 960
gggacgtacc accaccacca ccaccaccac caccaccatc cgagccccta ctcgccctac 1020
gtgggggcgc cactgacgcc tgcctggccc gccggaccct tcgagacccc ggtgctgcac 1080
agcctgcaga gccgcgccgg agccccgctc ccggtgcccc ggggtcccag tgcagacctg 1140
ctggaggacc tgtccgagag ccgcgagtgc gtgaactgcg gctccatcca gacgccgctg 1200
tggcggcggg acggcaccgg ccactacctg tgcaacgcct gcgggctcta cagcaagatg 1260
aacggcctca gccggcccct catcaagccg cagaagcgcg tgccttcatc acggcggctt 1320
ggattgtcct gtgccaactg tcacaccaca actaccacct tatggcgcag aaacgccgag 1380
ggtgaacccg tgtgcaatgc ttgtggactc tacatgaaac tccatggggt gcccagacca 1440
cttgctatga aaaaagaggg aattcaaacc aggaaacgaa aacctaagaa cataaataaa 1500
tcaaagactt gctctggtaa tagcaataat tccattccca tgactccaac ttccacctct 1560
tctaactcag atgattgcag caaaaatact tcccccacaa cacaacctac agcctcaggg 1620
gcgggtgccc cggtgatgac tggtgcggga gagagcacca atcccgagaa cagcgagctc 1680
aagtattcgg gtcaagatgg gctctacata ggcgtcagtc tcgcctcgcc ggccgaagtc 1740
acgtcctccg tgcgaccgga ttcctggtgc gccctggccc tggcctga 1788
<210> 2
<211> 595
<212> PRT
<213> Gata6
<400> 2
Met Ala Leu Thr Asp Gly Gly Trp Cys Leu Pro Lys Arg Phe Gly Ala
1 5 10 15
Ala Gly Ala Asp Ala Ser Asp Ser Arg Ala Phe Pro Ala Arg Glu Pro
20 25 30
Ser Thr Pro Pro Ser Pro Ile Ser Ser Ser Ser Ser Ser Cys Ser Arg
35 40 45
Gly Gly Glu Arg Gly Pro Gly Gly Ala Ser Asn Cys Gly Thr Pro Gln
50 55 60
Leu Asp Thr Glu Ala Ala Ala Gly Pro Pro Ala Arg Ser Leu Leu Leu
65 70 75 80
Ser Ser Tyr Ala Ser His Pro Phe Gly Ala Pro His Gly Pro Ser Ala
85 90 95
Pro Gly Val Ala Gly Pro Gly Gly Asn Leu Ser Ser Trp Glu Asp Leu
100 105 110
Leu Leu Phe Thr Asp Leu Asp Gln Ala Ala Thr Ala Ser Lys Leu Leu
115 120 125
Trp Ser Ser Arg Gly Ala Lys Leu Ser Pro Phe Ala Pro Glu Gln Pro
130 135 140
Glu Glu Met Tyr Gln Thr Leu Ala Ala Leu Ser Ser Gln Gly Pro Ala
145 150 155 160
Ala Tyr Asp Gly Ala Pro Gly Gly Phe Val His Ser Ala Ala Ala Ala
165 170 175
Ala Ala Ala Ala Ala Ala Ala Ser Ser Pro Val Tyr Val Pro Thr Thr
180 185 190
Arg Val Gly Ser Met Leu Pro Gly Leu Pro Tyr His Leu Gln Gly Ser
195 200 205
Gly Ser Gly Pro Ala Asn His Ala Gly Gly Ala Gly Ala His Pro Gly
210 215 220
Trp Pro Gln Ala Ser Ala Asp Ser Pro Pro Tyr Gly Ser Gly Gly Gly
225 230 235 240
Ala Ala Gly Gly Gly Ala Ala Gly Pro Gly Gly Ala Gly Ser Ala Ala
245 250 255
Ala His Val Ser Ala Arg Phe Pro Tyr Ser Pro Ser Pro Pro Met Ala
260 265 270
Asn Gly Ala Ala Arg Glu Pro Gly Gly Tyr Ala Ala Ala Gly Ser Gly
275 280 285
Gly Ala Gly Gly Val Ser Gly Gly Gly Ser Ser Leu Ala Ala Met Gly
290 295 300
Gly Arg Glu Pro Gln Tyr Ser Ser Leu Ser Ala Ala Arg Pro Leu Asn
305 310 315 320
Gly Thr Tyr His His His His His His His His His His Pro Ser Pro
325 330 335
Tyr Ser Pro Tyr Val Gly Ala Pro Leu Thr Pro Ala Trp Pro Ala Gly
340 345 350
Pro Phe Glu Thr Pro Val Leu His Ser Leu Gln Ser Arg Ala Gly Ala
355 360 365
Pro Leu Pro Val Pro Arg Gly Pro Ser Ala Asp Leu Leu Glu Asp Leu
370 375 380
Ser Glu Ser Arg Glu Cys Val Asn Cys Gly Ser Ile Gln Thr Pro Leu
385 390 395 400
Trp Arg Arg Asp Gly Thr Gly His Tyr Leu Cys Asn Ala Cys Gly Leu
405 410 415
Tyr Ser Lys Met Asn Gly Leu Ser Arg Pro Leu Ile Lys Pro Gln Lys
420 425 430
Arg Val Pro Ser Ser Arg Arg Leu Gly Leu Ser Cys Ala Asn Cys His
435 440 445
Thr Thr Thr Thr Thr Leu Trp Arg Arg Asn Ala Glu Gly Glu Pro Val
450 455 460
Cys Asn Ala Cys Gly Leu Tyr Met Lys Leu His Gly Val Pro Arg Pro
465 470 475 480
Leu Ala Met Lys Lys Glu Gly Ile Gln Thr Arg Lys Arg Lys Pro Lys
485 490 495
Asn Ile Asn Lys Ser Lys Thr Cys Ser Gly Asn Ser Asn Asn Ser Ile
500 505 510
Pro Met Thr Pro Thr Ser Thr Ser Ser Asn Ser Asp Asp Cys Ser Lys
515 520 525
Asn Thr Ser Pro Thr Thr Gln Pro Thr Ala Ser Gly Ala Gly Ala Pro
530 535 540
Val Met Thr Gly Ala Gly Glu Ser Thr Asn Pro Glu Asn Ser Glu Leu
545 550 555 560
Lys Tyr Ser Gly Gln Asp Gly Leu Tyr Ile Gly Val Ser Leu Ala Ser
565 570 575
Pro Ala Glu Val Thr Ser Ser Val Arg Pro Asp Ser Trp Cys Ala Leu
580 585 590
Ala Leu Ala
595
<210> 1
<211> 1332
<212> DNA
<213> Gata4
<400> 1
atgtatcaga gcttggccat ggccgccaac cacgggccgc cccccggtgc ctacgaggcg 60
ggcggccccg gcgccttcat gcacggcgcg ggcgccgcgt cctcgccagt ctacgtgccc 120
acaccgcggg tgccctcctc cgtgctgggc ctgtcctacc tccagggcgg aggcgcgggc 180
tctgcgtccg gaggcgcctc gggcggcagc tccggtgggg ccgcgtctgg tgcggggccc 240
gggacccagc agggcagccc gggatggagc caggcgggag ccgacggagc cgcttacacc 300
ccgccgccgg tgtcgccgcg cttctccttc ccggggacca ccgggtccct ggcggccgcc 360
gccgccgctg ccgcggcccg ggaagctgcg gcctacagca gtggcggcgg agcggcgggt 420
gcgggcctgg cgggccgcga gcagtacggg cgcgccggct tcgcgggctc ctactccagc 480
ccctacccgg cttacatggc cgacgtgggc gcgtcctggg ccgcagccgc cgccgcctcc 540
gccggcccct tcgacagccc ggtcctgcac agcctgcccg gccgggccaa cccggccgcc 600
cgacacccca atctcgtaga tatgtttgac gacttctcag aaggcagaga gtgtgtcaac 660
tgtggggcta tgtccacccc gctctggagg cgagatggga cgggtcacta tctgtgcaac 720
gcctgcggcc tctaccacaa gatgaacggc atcaaccggc cgctcatcaa gcctcagcgc 780
cggctgtccg cctcccgccg agtgggcctc tcctgtgcca actgccagac caccaccacc 840
acgctgtggc gccgcaatgc ggagggcgag cctgtgtgca atgcctgcgg cctctacatg 900
aagctccacg gggtccccag gcctcttgca atgcggaaag aggggatcca aaccagaaaa 960
cggaagccca agaacctgaa taaatctaag acaccagcag ctccttcagg cagtgagagc 1020
cttcctcccg ccagcggtgc ttccagcaac tccagcaacg ccaccaccag cagcagcgag 1080
gagatgcgtc ccatcaagac ggagcctggc ctgtcatctc actacgggca cagcagctcc 1140
gtgtcccaga cgttctcagt cagtgcgatg tctggccatg ggccctccat ccaccctgtc 1200
ctctcggccc tgaagctctc cccacaaggc tatgcgtctc ccgtcagcca gtctccacag 1260
accagctcca agcaggactc ttggaacagc ctggtcttgg ccgacagtca cggggacata 1320
atcactgcgt aa 1332
<210> 14
<211> 443
<212> PRT
<213> Gata4
<400> 14
Met Tyr Gln Ser Leu Ala Met Ala Ala Asn His Gly Pro Pro Pro Gly
1 5 10 15
Ala Tyr Glu Ala Gly Gly Pro Gly Ala Phe Met His Gly Ala Gly Ala
20 25 30
Ala Ser Ser Pro Val Tyr Val Pro Thr Pro Arg Val Pro Ser Ser Val
35 40 45
Leu Gly Leu Ser Tyr Leu Gln Gly Gly Gly Ala Gly Ser Ala Ser Gly
50 55 60
Gly Ala Ser Gly Gly Ser Ser Gly Gly Ala Ala Ser Gly Ala Gly Pro
65 70 75 80
Gly Thr Gln Gln Gly Ser Pro Gly Trp Ser Gln Ala Gly Ala Asp Gly
85 90 95
Ala Ala Tyr Thr Pro Pro Pro Val Ser Pro Arg Phe Ser Phe Pro Gly
100 105 110
Thr Thr Gly Ser Leu Ala Ala Ala Ala Ala Ala Ala Ala Ala Arg Glu
115 120 125
Ala Ala Ala Tyr Ser Ser Gly Gly Gly Ala Ala Gly Ala Gly Leu Ala
130 135 140
Gly Arg Glu Gln Tyr Gly Arg Ala Gly Phe Ala Gly Ser Tyr Ser Ser
145 150 155 160
Pro Tyr Pro Ala Tyr Met Ala Asp Val Gly Ala Ser Trp Ala Ala Ala
165 170 175
Ala Ala Ala Ser Ala Gly Pro Phe Asp Ser Pro Val Leu His Ser Leu
180 185 190
Pro Gly Arg Ala Asn Pro Ala Ala Arg His Pro Asn Leu Val Asp Met
195 200 205
Phe Asp Asp Phe Ser Glu Gly Arg Glu Cys Val Asn Cys Gly Ala Met
210 215 220
Ser Thr Pro Leu Trp Arg Arg Asp Gly Thr Gly His Tyr Leu Cys Asn
225 230 235 240
Ala Cys Gly Leu Tyr His Lys Met Asn Gly Ile Asn Arg Pro Leu Ile
245 250 255
Lys Pro Gln Arg Arg Leu Ser Ala Ser Arg Arg Val Gly Leu Ser Cys
260 265 270
Ala Asn Cys Gln Thr Thr Thr Thr Thr Leu Trp Arg Arg Asn Ala Glu
275 280 285
Gly Glu Pro Val Cys Asn Ala Cys Gly Leu Tyr Met Lys Leu His Gly
290 295 300
Val Pro Arg Pro Leu Ala Met Arg Lys Glu Gly Ile Gln Thr Arg Lys
305 310 315 320
Arg Lys Pro Lys Asn Leu Asn Lys Ser Lys Thr Pro Ala Ala Pro Ser
325 330 335
Gly Ser Glu Ser Leu Pro Pro Ala Ser Gly Ala Ser Ser Asn Ser Ser
340 345 350
Asn Ala Thr Thr Ser Ser Ser Glu Glu Met Arg Pro Ile Lys Thr Glu
355 360 365
Pro Gly Leu Ser Ser His Tyr Gly His Ser Ser Ser Val Ser Gln Thr
370 375 380
Phe Ser Val Ser Ala Met Ser Gly His Gly Pro Ser Ile His Pro Val
385 390 395 400
Leu Ser Ala Leu Lys Leu Ser Pro Gln Gly Tyr Ala Ser Pro Val Ser
405 410 415
Gln Ser Pro Gln Thr Ser Ser Lys Gln Asp Ser Trp Asn Ser Leu Val
420 425 430
Leu Ala Asp Ser His Gly Asp Ile Ile Thr Ala
435 440

Claims (2)

1.一种维持人胚胎干细胞自我更新状态的培养方法,其特征在于,包括以下步骤:
(1)人的胚胎干细胞HES2或H9的获取;
(2)人的胚胎干细胞HES2或H9在Activin A+bFGF+IWR1条件下的传代和培养:
a、取一个6 孔细胞培养板,每孔用1.8-2.1ml DMEM+8-12µl Matrigel包板,置于35-38℃、4.5-5.5% CO2浓度的细胞培养箱内,包被3.8-4.2小时;
b、取生长至70-80% 密度的人的胚胎干细胞,弃培养液,用PBS洗涤细胞1次,以除去细胞表面残留的培养液;
c、加入0.9-1.1ml CTK消化胚胎干细胞,6.5-7.5min,细胞边缘浮起,弃CTK,加1.6-2.4ml含9-12%FBS的常规细胞培养液,用移液器吹打,将细胞从培养板上吹打下来,然后转移至15ml无菌离心管中;
d、转速1100-1300 rpm,离心3.5-4.5min后,吸去上清;
e、加1.8-2.2ml含9.6-10.2%KSR的N2B27重悬细胞;
其中,5ml N2B27含1.875ml DMEM/F12,0.25ml N2,1.875ml Neurobasal培养基,0.5ml B27, 2 mM L-谷氨酰胺, 0.1 mM β-巯基乙醇;
f、在显微镜下利用血球计数板对悬液中的细胞进行计数,并以此计算出细胞的密度;
g、取步骤a已包被好的培养皿,弃包板溶液,向培养板每孔内加入1.8-2.2 ml N2B27+KSR培养基;
h、向培养基中加入3.8×104-4.1×104个细胞,水平十字形晃动,使细胞均匀分布;
i、依次添加3.9-4.2μM IWR1、4.9-5.2 ng Activin A和4.9-5.2 ng bFGF,水平十字形晃动,使其混合均匀,为实验组;
j、将细胞培养皿置于35-38℃、4-6% CO2浓度的细胞培养箱内培养,即可。
2.根据权利要求1所述的一种维持人胚胎干细胞自我更新状态的培养方法,其特征在于,所述消化胚胎干细胞的CTK含0.09-0.12% 胶原酶IV+0.24-0.26% 胰蛋白酶+19-21%KSR+0.9-1.1 mM CaCl2的PBS。
CN201711223223.4A 2017-11-29 2017-11-29 一种维持人胚胎干细胞自我更新状态的培养方法 Active CN108018259B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711223223.4A CN108018259B (zh) 2017-11-29 2017-11-29 一种维持人胚胎干细胞自我更新状态的培养方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711223223.4A CN108018259B (zh) 2017-11-29 2017-11-29 一种维持人胚胎干细胞自我更新状态的培养方法

Publications (2)

Publication Number Publication Date
CN108018259A CN108018259A (zh) 2018-05-11
CN108018259B true CN108018259B (zh) 2019-11-22

Family

ID=62077458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711223223.4A Active CN108018259B (zh) 2017-11-29 2017-11-29 一种维持人胚胎干细胞自我更新状态的培养方法

Country Status (1)

Country Link
CN (1) CN108018259B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109722411B (zh) * 2019-03-01 2022-05-06 安徽大学 一种促进胚胎干细胞自我更新状态的小分子的应用方法
CN113234667A (zh) * 2021-05-08 2021-08-10 杭州憶盛医疗科技有限公司 一种多能干细胞的建立与干性维持方法
CN115029302B (zh) * 2022-06-10 2023-07-11 安徽大学 一种维持小鼠胚胎干细胞干性的培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106635966A (zh) * 2017-03-01 2017-05-10 安徽大学 一种维持小鼠上胚层干细胞自我更新状态的培养方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106635966A (zh) * 2017-03-01 2017-05-10 安徽大学 一种维持小鼠上胚层干细胞自我更新状态的培养方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
β-catenin coordinates with Jup and the TCF1/GATA6 axis to regulate human embryonic stem cell fate;Hongwei Sun等;《Developmental Biology》;20170921;第431卷(第2期);第279页右栏4.1 *

Also Published As

Publication number Publication date
CN108018259A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
CN108018259B (zh) 一种维持人胚胎干细胞自我更新状态的培养方法
CN106635966B (zh) 一种维持小鼠上胚层干细胞自我更新状态的培养方法
CN108795850B (zh) 一种精原干细胞体外无饲养层长期培养方法
CN102304491A (zh) 半滑舌鳎精巢细胞系的构建与鉴定方法
CN110564821A (zh) 用于黄瓜幼苗基因定位研究的rna原位杂交优化方法
CN115747140A (zh) 一种诱导鸡胚胎干细胞分化生成原始生殖细胞的方法
WO2023010852A1 (zh) 融合成像基因及其慢病毒表达质粒、慢病毒、细胞,其制备方法和用途
Bhatia et al. Introduction to animal tissue culture science
CN102978154B (zh) 一种同时分离内蒙古白绒山羊皮肤成纤维细胞和表皮细胞的原代培养方法
AU2021101223A4 (en) METHOD FOR LONG-TERM IN VITRO CULTURE OF CHICKEN PGCs
CN109722411B (zh) 一种促进胚胎干细胞自我更新状态的小分子的应用方法
CN106755507B (zh) 鉴别栽培黑麦与野生黑麦染色体的分子检测方法
Khurad et al. A new Bombyx mori larval ovarian cell line highly susceptible to nucleopolyhedrovirus
CN1737130A (zh) 花鲈胚胎干细胞及培养方法
CN105288608A (zh) 猪圆环病毒2型灭活疫苗连续收毒悬浮培养生产方法
CN112695010B (zh) 高产杆状病毒的棉铃虫蛹卵巢细胞系及其制备方法和应用
CN108715869B (zh) 一种基于获取特定供体细胞提高哺乳动物克隆效率的方法
CN101892155B (zh) 一种羊水/绒毛膜细胞原位培养专用培养装置及应用
CN113817653A (zh) 一株荧光假单胞菌BsEB-1及其应用
CN111893088A (zh) 一种体外分离培养蒙古马睾丸精原干细胞的方法
CN103602630A (zh) 一种宫颈上皮内瘤变细胞的体外培养方法
CN102174577A (zh) 一种利用慢病毒载体生产转基因水牛的方法
CN102453697A (zh) 悬浮培养Vero细胞及利用其生产病毒疫苗的方法
CN105950548A (zh) 一种从间充质干细胞高效获取可跳动有功能心肌细胞的方法
CN111454885A (zh) 巴氏综合症可诱导多功能干细胞及其制备方法和分化培养基和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant